These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1595 related items for PubMed ID: 17352762

  • 1. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [Abstract] [Full Text] [Related]

  • 2. The prognosis of highly active antiretroviral therapy (HAART) treated HIV infected patients in Serbia, related to the time of treatment initiation.
    Jevtović Dj, Salemović D, Ranin J, Dulović O, Ilić D, Brmbolić B.
    J Clin Virol; 2010 Feb; 47(2):131-5. PubMed ID: 20006540
    [Abstract] [Full Text] [Related]

  • 3. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.
    Clin Infect Dis; 2006 Jan 01; 42(1):136-44. PubMed ID: 16323104
    [Abstract] [Full Text] [Related]

  • 4. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.
    Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110
    [Abstract] [Full Text] [Related]

  • 5. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A, Spanish Group of Paediatric HIV Infection.
    Clin Infect Dis; 2006 Mar 15; 42(6):862-9. PubMed ID: 16477566
    [Abstract] [Full Text] [Related]

  • 6. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH, Chan KC, Lee SS.
    Clin Infect Dis; 2004 Sep 15; 39(6):853-60. PubMed ID: 15472819
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S, CoRIS-MD.
    PLoS One; 2006 Dec 20; 1(1):e89. PubMed ID: 17183720
    [Abstract] [Full Text] [Related]

  • 8. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A.
    Antivir Ther; 2010 Dec 20; 15(2):165-75. PubMed ID: 20386071
    [Abstract] [Full Text] [Related]

  • 9. The dissociation between virological and immunological responses to HAART.
    Jevtović D, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.
    Biomed Pharmacother; 2005 Sep 20; 59(8):446-51. PubMed ID: 16140494
    [Abstract] [Full Text] [Related]

  • 10. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.
    Jevtović Dj, Ranin J, Salemović D, Pesić I, Dragović G, Zerjav S, Djurković-Djaković O.
    Biomed Pharmacother; 2008 Jan 20; 62(1):21-5. PubMed ID: 17223307
    [Abstract] [Full Text] [Related]

  • 11. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR, Pediatric AIDS Clinical Trials Group 219/219C Study Team.
    Clin Infect Dis; 2008 Feb 15; 46(4):507-15. PubMed ID: 18199042
    [Abstract] [Full Text] [Related]

  • 12. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT.
    AIDS; 2006 May 12; 20(8):1171-9. PubMed ID: 16691069
    [Abstract] [Full Text] [Related]

  • 13. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 14. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.
    Pharmacotherapy; 2008 Mar 01; 28(3):323-30. PubMed ID: 18294112
    [Abstract] [Full Text] [Related]

  • 15. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.
    Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741
    [Abstract] [Full Text] [Related]

  • 16. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH, Weis N, Skinhøj P, Laursen A, Christensen PB, Nielsen HI, Møller A, Engsig F, Sørensen HT, Obel N.
    HIV Med; 2008 May 01; 9(5):300-6. PubMed ID: 18400077
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P, de Górgolas M, Estrada V, Arranz A, Rivas P, Yera C, García R, Granizo JJ, Fernández-Guerrero M.
    Clin Infect Dis; 2004 Oct 01; 39(7):1024-9. PubMed ID: 15472856
    [Abstract] [Full Text] [Related]

  • 18. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, Hogg RS, Montaner JS.
    J Infect Dis; 2006 Jan 15; 193(2):259-68. PubMed ID: 16362890
    [Abstract] [Full Text] [Related]

  • 19. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.
    HIV Med; 2007 May 15; 8(4):213-9. PubMed ID: 17461848
    [Abstract] [Full Text] [Related]

  • 20. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
    Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS.
    CMAJ; 1999 Mar 09; 160(5):659-65. PubMed ID: 10102000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.